CATX — Perspective Therapeutics Share News
0.000.00%
Last trade - 00:00- $183.78m
- -$51.49m
- $0.88m
U.S. RESEARCH ROUNDUP-Beauty Health, Design Therapeutics, Energizer Holdings
Brief: Perspective Therapeutics Q3 revenue USD 2.19 million
Brief: Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors
Brief: Perspective Therapeutics Completes Recruitment For First Patient Cohort In Phase 1/2a Dose Escalation Trial Of VMT01 In Malignant Melanoma
Brief: Perspective Therapeutics’ VMT-Α-NET Protocols Presented At The North American Neuroendocrine Tumor Society (Nanets) 2023 Symposium
Brief: Perspective Announces Presentation Of Positive Early Clinical Data For VMT-α-NET
Brief: Perspective Therapeutics Announces First Patient Dosed In Phase 1/2A Dose Escalation Trial For Treatment Of MC1R-Positive Metastatic Melanoma
Brief: Perspective Therapeutics And GT Medical Technologies Collaborate To Expand Access To Unique Cesium-131 Based Brain Cancer Treatment
Brief: Perspective Therapeutics Says On July 10, Terminated Employment Of COO Jennifer Streeter
Brief: Perspective Therapeutics Initiates Phase 1/2a Clinical Trials For Two Targeted Alpha Therapy Oncology Product Candidates
Brief: Perspective Therapeutics, PharmaLogic Announce Collaboration For Development, Production Of Theranostics For Cancer Care
Brief: Perspective Therapeutics Has No Cash, Cash Equivalents With Silicon Valley Bank Or Signature Bank